The vertical reality
Cell and gene therapy manufacturing does not look like standard pharmaceutical batch manufacturing, and it does not look like standard discrete manufacturing either. A single patient dose travels a chain of custody from collection through shipping to manufacturing and back to delivery, with costs and compliance obligations at each step. But a generalist NetSuite implementer, no matter how experienced with standard manufacturing or standard pharma clients, has typically never configured a system around this pattern before.
When a generalist firm does the implementation, the usual result is a system that does standard inventory and standard batch manufacturing well enough, but simply does not have the patient-level traceability and suite capacity accounting the business actually requires. That gap will be discovered in the first FDA inspection or the first investor diligence review, not in the implementation.
How NetSuite can help
NetSuite absolutely can handle the vein-to-vein tracking, suite scheduling and dose-level cost accounting that cell and gene therapy manufacturing demands. The platform is not the bottleneck. That configuration is. And if you want to do it right you have to understand the real chain of custody and manufacturing model before you write your first workflow.
This is a design problem before it is a technical one. Getting the location structure, item tracking and cost accumulation right at the time of implementation avoids the costly rebuild once the gaps in a generic config become visible.
Why Archer Insights
Archer Insights specializes in NetSuite for life sciences and healthcare organizations and that includes direct experience with the specific traceability and manufacturing suite accounting patterns cell and gene therapy companies need. When searching for an implementation partner for this vertical, the right question is not if they know NetSuite. It is if they have previously set it up for a single-patient-dose manufacturing model.